Vincent B N, Morrison R N, Nowak B F
Aquafin CRC, School of Aquaculture, Tasmanian Aquaculture and Fisheries Institute, University of Tasmania, Launceston, Tasmania, Australia.
J Fish Dis. 2006 Sep;29(9):549-59. doi: 10.1111/j.1365-2761.2006.00751.x.
There is inconsistent evidence of resistance of Atlantic salmon, Salmo salar L., to amoebic gill disease (AGD). Here, evidence is presented that demonstrates that Atlantic salmon exposed and subsequently challenged with AGD are more resistant than naïve control fish. Seventy-three per cent of Atlantic salmon previously exposed to AGD survived to day 35 post-challenge compared with 26% exposed to Neoparamoeba sp. for the first time, yet the gill pathology of surviving naïve control or previously exposed fish was not significantly different. Development of resistance to AGD is associated with anti-Neoparamoeba sp. antibodies that were detectable in serum of 50% of surviving Atlantic salmon previously exposed to AGD. However, anti-Neoparamoeba sp. antibodies were not detectable in cutaneous mucus of resistant fish. Increased resistance of Atlantic salmon after secondary Neoparamoeba sp. infection and detection of specific serum antibodies provides support for the development of a vaccine for AGD.
关于大西洋鲑（Salmo salar L.）对阿米巴鳃病（AGD）的抗性，证据并不一致。在此，有证据表明，接触过AGD并随后受到挑战的大西洋鲑比未接触过的对照鱼更具抗性。先前接触过AGD的大西洋鲑中有73%在攻毒后35天存活下来，而首次接触新帕拉变形虫属（Neoparamoeba sp.）的鱼存活率为26%，然而，存活的未接触过AGD的对照鱼或先前接触过AGD的鱼的鳃部病理变化并无显著差异。对AGD抗性的产生与抗新帕拉变形虫属抗体有关，在先前接触过AGD的存活大西洋鲑中，50%的鱼血清中可检测到这种抗体。然而，在抗性鱼的皮肤黏液中未检测到抗新帕拉变形虫属抗体。二次感染新帕拉变形虫属后大西洋鲑抗性增强以及特异性血清抗体的检测，为开发AGD疫苗提供了支持。
